Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604816 | 0.91 | GPR119 (0.36) | USP30NR1H2NR1H3 | |
| SCHEMBL3603893 | 0.89 | USP30 (0.35) | USP30NR1H2NR1H3SLC5A1DDB1 | |
| SCHEMBL3595736 | 0.89 | FKBP1A (0.36) | USP30NR1H2NR1H3SLC5A1DDB1 | |
| SCHEMBL3605596 | 0.89 | ALDH1A1 (0.37) | DDB1CRBN | |
| SCHEMBL3606731 | 0.88 | OPRM1 (0.38) | USP30NR1H2NR1H3DDB1CRBN | |
| SCHEMBL3601055 | 0.88 | GPR119 (0.41) | NR1H2NR1H3 | |
| SCHEMBL3597127 | 0.88 | DDB1 (0.34) | USP30NR1H2NR1H3DDB1CRBN | |
| SCHEMBL3606120 | 0.88 | POLB (0.37) | DDB1CRBN | |
| SCHEMBL3610736 | 0.87 | ALDH1A1 (0.35) | USP30NR1H2NR1H3SLC5A1DDB1 | |
| SCHEMBL3609983 | 0.87 | ALDH1A1 (0.36) | USP30NR1H2NR1H3DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | USP30 4815/4885NR1H2 1861/4885NR1H3 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.